29 results about "Neuropeptide" patented technology

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.

The present invention relates to insect neuropeptide compounds of the family of pyroglutamic peptides and analogs thereof having activity against insects, such as Hemiptera, Diptera, Lepidoptera, Blattaria and / or Coleoptera insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The present invention relates to analogues of insect neuropeptides that are active against insects, such as Diptera, Hemiptera, Blattodea and / or Lepidoptera, and to the use of these as insect control agents (e.g., insecticides) and plant protection agents.

The invention relates to the technical field of medicines, in particular to application of a neuropeptide Y1 receptor antagonist in preparation of a hereditary polycystic kidney disease treatment medicine. The neuropeptide Y1 receptor antagonist is selected from a compound BIBO3304 which plays a role in blocking combination of neuropeptide Y (NPY) and a Y1 receptor subtype thereof. On the basis that early-stage histopathology, high-throughput sequencing, cytobiology and molecular biology are combined with in-vitro cell culture and in-vivo animal experiments, the potential treatment effect of the neuropeptide Y1 receptor antagonist in preparation of hereditary polycystic kidney disease treatment drugs is provided, and a new basis is provided for hereditary polycystic kidney disease treatment.

Failures in establishing trust during international conflict negotiations frequently result in warfare, as ideological differences often cannot be resolved through rational discourse alone. Empathy between opposing parties is essential for building trust, and oxytocin is recognized for its critical role in facilitating empathy, trust, inter-brain synchrony, and cooperative decision-making. However, prevailing scientific studies typically do not differentiate between the cis and trans isomers of oxytocin, despite evidence that only the trans isomer is pharmacologically active. The present invention provides methods for the separation and quantification of oxytocin isomers, with particular emphasis on the trans isomer's function in social synchrony and decision-making within conflict negotiation contexts. Additionally, the invention explores the role of extremely low frequency electromagnetic radiation permeating the human central nervous system interconnecting neurochemical changes among groups. These advances clarify the unique neuropeptide functions of oxytocin and enhance understanding of its impact on cooperation and conflict resolution.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The application discloses a novel insect short neuropeptide sNPF analogue and application thereof in pests, and relates to the technical field of agriculture; the application provides a structural general formula of the novel insect short neuropeptide sNPF analogue, and the novel insect short neuropeptide sNPF analogue is applied to the prevention and treatment of aphids, thrips, Plutella xylostella and Spodoptera frugiperda. The terminal tyrosine Y, arginine R or leucine L residue is substituted and modified by using hydrophilic, hydrophobic, steric hindrance natural amino acids or unnatural amino acids and other groups on a lead compound, and the obtained novel insect short neuropeptide sNPF analogue can be used in the prevention and treatment of various pests.

The invention particularly discloses dendritic poly-L-lysine modified PACAP as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The PACAP-DPL provided by the invention effectively overcomes the defect of insufficient in-vivo stability of natural PACAP on the premise of not weakening the biological function of PACAP, provides a new technical approach for the application of PACAP neuropeptides in Alzheimer's disease, and has good research value and potential application prospect.

The present invention relates to insect neuropeptide compounds of the AKH family and analogs thereof having activity against insects, such as hemiptera, diptera, lepidoptera, cockroaches and / or coleopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. Insecticides) and plant protection agents.

The present invention provides PYY analogs that are neuropeptide Y2 (NPY2) receptor agonists, their medical use in the treatment and / or prevention of various diseases, conditions, or disorders, such as the treatment and / or prevention of excessive food intake, excess weight, adiposity, metabolic diseases, and other conditions or disorders associated with excess weight or adiposity, such as diabetics and cardiovascular diseases.SOLUTION: The present invention relates to PYY analogues having alanine in position 4, lysine in position 7, QRY as C-terminus and a half-life extending group. The analogs of the present invention are soluble in pH6 and around 7. The invention also relates to pharmaceutical compositions comprising the PYY analogues and to pharmaceutical uses of the analogues.SELECTED DRAWING: None

Intranasal neuropeptide Y (NPY) analogs having D-amino acids, such as [D26-His]-NPY are provided for early intervention to prevent or to treat, to reverse, or reduce symptoms of stress-related impairments such as PTSD, depression, substance abuse, and / or memory deficits following exposure to traumatic or surgical stress.

The present disclosure relates to use of tear fluid neuropeptide Y (NPY) level for diagnosis, prognosis, assessment and therapy stratification of corneal nerve damage or loss, corneal neuropathy, corneal neuropathic pain, corneal neuralgia, ocular disease, or peripheral neuropathy.

The application discloses a neurotransmitter regulation interaction relationship model construction method and system, relates to the technical field of computational neuroscience, and comprises the following steps: constructing a neuron multimodal neurotransmitter co-release dynamics unit, defining small molecule neurotransmitter and neuropeptide respective vesicle pool state variables, and establishing a coupling release equation based on calcium dependence and regulatory protein selectivity, and outputting two types of neurotransmitter spatiotemporal release source terms; inputting the spatiotemporal release source terms into a three-dimensional brain space structure embedded with a receptor density map, solving a volume conduction equation, and generating a dynamic concentration field of a whole brain range of modulating neurotransmitters; according to a corresponding relationship between the dynamic concentration field and the local receptor density, calculating diffuse modulation input received by the neuron; based on the concentration of a specific modulating neurotransmitter in the dynamic concentration field, driving state evolution of an astrocyte cell unit, and outputting a concentration of a regulatory neurotransmitter released by the astrocyte cell; and integrating point-to-point synapse input, diffuse modulation input and the concentration of the regulatory neurotransmitter released by the astrocyte cell.

The disclosure provides a neural peptide prediction method and system based on sequence representation and multi-task learning, relating to the technical fields of biological information and artificial intelligence, comprising: obtaining a peptide amino acid sequence to be predicted; inputting the amino acid sequence into a neural peptide predictor, converting the amino acid sequence into a residue context representation through a sequence representation module of the neural peptide predictor, inputting the residue context representation into a sequence encoding module to capture context dependence at different positions and learn neural peptide discriminative features, and obtaining a feature matrix; aggregating the feature matrix through a feature aggregation module to obtain a fixed-length sequence-level vector; and a classification task module outputting whether the sequence belongs to a neural peptide according to the fixed-length sequence-level vector, and finally completing the prediction of the neural peptide. The disclosure improves the accuracy, robustness and cross-dataset generalization ability of neural peptide prediction.

The present invention relates to bifunctional insect neuropeptide compounds and analogs thereof having activity against insects, such as hemiptera, diptera, lepidoptera, cockroaches and / or coleopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. Insecticides) and plant protection agents.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and / or diagnosis of cancer.

The invention belongs to the technical field of biological medicine and functional food, and discloses a fermentation composition based on signal peptide induction, which is prepared by the following steps: step 1, mixing astragalus membranaceus, lotus leaf, poria cocos and pericarpium citri reticulatae according to the mass ratio of (3-5): (2-4): (2-3): (1-2) to prepare a compound raw material; the fermentation composition is remarkable in effect and multi-target, the food intake can be reduced by reducing mRNA expression of hypothalamus neuropeptide Y and rat-related peptide and increasing the content of glucagon-like peptide-1, lipid metabolism can be regulated and controlled by improving mRNA expression of liver farnesoid X receptors, AMP-dependent protein kinase and carnitine palmitoyl transferase-1, and the food intake can be reduced by increasing the content of glucagon-like peptide-1. The abundance of intestinal bifidobacteria can be improved, and the expression of brown fat heat production related genes is promoted to balance intestinal flora; the safety of the composition is subjected to dual verification of animal and crowd tests, the weight and blood fat indexes of obese rats and obese crowds are remarkably improved, and the liver and kidney functions are not damaged.

Compositions and methods for the management and treatment of obesity, metabolic disorders, nausea and emesis using a ODN peptides and synthetic derivatives thereof are disclosed.

The present invention relates to natural or natural-like analogues of insect pyrokinin neuropeptide [Hy]-SPPYSPPFSPRL-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and / or coleopteran insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and / or diagnosis of cancer.

Provided herein are synthetic peptides developed from slug and insect neuropeptides. Peptides described can be used to repel, control or deter slugs, including the gray garden slug (Deroceras reticulatum), from feeding on agricultural and horticultural plants. The peptides can be combined with bait materials, or applied directly to plants or areas, or produced by genetically modified plants.

Disclosed are synthetic peptides developed from the western flower thrip (Frankliniella occidentalis), spotted-wing drosophila (Drosophila suzukii), diamondback moth (Plutella xylostella), lygus (Lygus Hesperus), and other insect neuropeptides. Peptides disclosed can be used to repel, control, or deter Frankliniella spp., Drosophila spp., Plutella ssp., and Lygus ssp., including Frankliniella occidentalis, Drosophila suzukii, Plutellaxylostella, and Lygus Hesperus from feeding on agricultural and horticultural plants. The peptides can be combined with bait materials, or applied directly to plants or areas.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of umbilical cord mesenchymal stem cells and application of the recombinant polypeptide. The invention discloses a recombinant polypeptide for improving the activity of umbilical cord mesenchymal stem cells. The amino acid sequence of the recombinant polypeptide is shown as SEQ ID NO. 1. The recombinant polypeptide disclosed by the invention is prepared by integrating pancreatic polypeptide and neuropeptide Y amino acid sequences and adopting a solid-phase synthesis method. The umbilical cord mesenchymal stem cells obtained by culturing the recombinant polypeptide have good multiplication capacity, also have the effect of inhibiting aging of the umbilical cord mesenchymal stem cells, and have wide application prospects.

The invention relates to the technical field of hydrogel, in particular to functional hydrogel of antibacterial healing-promoting fusion polypeptide as well as a preparation method and application of the functional hydrogel. The self-assembled peptide RADA16 is adopted as a hydrogel base material, and the neuropeptide and the antibacterial peptide are combined, so that the double effects of healing promotion and bacterium resistance of the hydrogel material are realized. The polypeptide and the degradation product amino acid are non-toxic and low in immunogenicity, and the polypeptide hydrogel has huge potential as a wound dressing by virtue of the natural source, biocompatibility and biosafety of the polypeptide hydrogel.